Journal des sciences biomédicales

  • ISSN: 2254-609X
  • Indice h du journal: 15
  • Note de citation du journal: 5.60
  • Facteur d’impact du journal: 4.85
Indexé dans
  • Genamics JournalSeek
  • Infrastructure nationale des connaissances en Chine (CNKI)
  • Répertoire d'indexation des revues de recherche (DRJI)
  • OCLC - WorldCat
  • Google Scholar
  • SHERPA ROMÉO
  • Laboratoires secrets des moteurs de recherche
Partager cette page

Abstrait

miRNA Profiling in MCF-7 Breast Cancer Cells: Seeking a New Biomarker

Hussein Sabit, Emre Cevik, Huseyin Tombuloglu, Katrine Farag, Osama AM Said, Shaimaa E Abdel-Ghany, Amany I Alqosaibi, Huseyin Bekir Yildiz, Ferhad Serag ElDeen, Eman Wagih6 and Mokhtar El-Zawahri

Cancer is an out-of-control cell proliferation that can attack any cell in the human body. One of the most prevailed cancers in women is breast cancer, with elevated incidence and mortality rates, that makes it a major health threat globally. In the present investigation, we used MCF-7 breast cancer cells to identify the role of 25 different miRNAs. The study revealed that out of the 25 miRNAs profiled, 11 miRNAs were upregulated, and 14 miRNAs were downregulated. Target gene prediction was conducted using MirNet online web building tool, and results indicated that up-regulated miRNAs interact with several cancer-related genes such as FRS2, TNFRSF10B, BTBD7, MYC, and TPRG1L. The down-regulated miRNAs were also interacting with a list of tumor-related genes (e.g., GABPB2, GNB1, CCND1, ERCC1, ZNF417, GLO1, EIF4G2, DRAXIN, HOXD11, and KPNA6). Disease prediction has also been conducted to identify the relatedness of, especially, the up-regulated miRNA with common disease including cancer. This study concludes that the 11 up-regulated miRNAs could be used as biomarkers to early diagnose BC, but we can highlight hsa-miR-30d-5p as a potential biomarker for its high expression profile. However, these data need more investigations to confirm this finding.

Avertissement: Ce résumé a été traduit à l'aide d'outils d'intelligence artificielle et n'a pas encore été examiné ni vérifié